



(51) International Patent Classification:

C12Q 1/68 (2006.01) *A61K 31/337* (2006.01)
A61P 35/00 (2006.01) *A61K 31/704* (2006.01)
G06F 19/20 (2011.01)

(21) International Application Number:

PCT/CA2013/000408

(22) International Filing Date:

24 April 2013 (24.04.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/637,676 24 April 2012 (24.04.2012) US
 61/806,222 28 March 2013 (28.03.2013) US

(71) Applicant: **RNA DIAGNOSTICS INC.** [CA/CA]; 595 Bay St., Suite 1204, P.O. Box 75, Toronto, Ontario M5G 2C2 (CA).

(72) Inventors; and


(71) Applicants : **PRITZKER, Kenneth** [CA/CA]; 19 Glencairn Ave., Toronto, Ontario M4R 1N1 (CA). **PARISENTI, Amadeo Mark** [CA/CA]; 62 Windsor Crescent, Sudbury, Ontario P3E 1Z7 (CA). **PRITZKER, Laura** [CA/CA]; 4 Ballacaine Drive, Toronto, Ontario M8Y 4A4 (CA). **ZHU, Mu** [CA/CA]; 502 Innsbruck Place, Waterloo, Ontario N2V 2N9 (CA). **WANG, Xiaohui** [CA/CA]; 252-350 Columbia Street West, Waterloo, Ontario N2L 6P6 (CA). **SANTI, Stacey** [CA/CA]; 10 Dow Drive, Unit 19, P.O. Box 724, Copper Cliff, Ontario P0M 1N0 (CA). **NARENDRULA, Rashmi** [CA/CA]; 1960B Paris Street, #111, Sudbury, Ontario P3E 4V3 (CA).

(74) Agent: **BERESKIN & PARR LLP/S.E.N.C.R.L., s.r.l.**; Scotia Plaza, 40 King Street West, 40th Floor, Toronto, Ontario M5H 3Y2 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

[Continued on next page]

(54) Title: ASSAYS, METHODS AND APPARATUS FOR ASSESSING RNA DISRUPTION

**FIG. 5A**

(57) Abstract: Various embodiments are described herein related to an assay, method and apparatus for performing an RNA Disruption Assay (RDA) for cellular RNA optionally in response to a cytotoxic treatment such as chemotherapy and/or radiation treatment. The method comprises obtaining at least one electropherogram dataset corresponding to a unique biological sample comprising the cellular RNA at a time point, optionally during or after the treatment; determining values for features from at least two shifted regions of the at least one electropherogram dataset, the shifting being due to the treatment; and optionally determining an RDA score based on a combination of the values of the features.



HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,

Published:

— *with international search report (Art. 21(3))*